Frederik Fierens
Brussels, BRU, Belgium
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Correction: Certolizumab Pegol for the Treatment of Plaque Psoriasis in Routine Clinical Practice: One-Year Results from the CIMREAL Study.
Journal: Dermatology and therapy
Published: September 28, 2024
Certolizumab pegol for plaque psoriasis in women of childbearing potential, pregnant or breastfeeding in clinical settings: One-year outcomes from the international noninterventional CIMREAL study.
Journal: Journal of the European Academy of Dermatology and Venereology : JEADV
Published: June 18, 2024
Certolizumab Pegol for the Treatment of Plaque Psoriasis in Routine Clinical Practice: One-Year Results from the CIMREAL Study.
Journal: Dermatology and therapy
Published: April 30, 2024
Publisher Correction: Long-Term Health-Related Quality of Life in Patients with Plaque Psoriasis Treated with Certolizumab Pegol: Three-Year Results from Two Randomised Phase 3 Studies (CIMPASI-1 and CIMPASI-2).
Journal: Dermatology and therapy
Published: May 30, 2023
Long-Term Health-Related Quality of Life in Patients with Plaque Psoriasis Treated with Certolizumab Pegol: Three-Year Results from Two Randomised Phase 3 Studies (CIMPASI-1 and CIMPASI-2).
Journal: Dermatology and therapy
Published: October 05, 2022
Three-year efficacy and safety of certolizumab pegol for the treatment of plaque psoriasis: results from the randomized phase 3 CIMPACT trial.
Journal: Journal of the European Academy of Dermatology and Venereology : JEADV
Published: February 23, 2021
Hexavalent vaccines: increasing options for policy-makers and providers. A review of the data supporting interchangeability (substitution with vaccines containing fewer antigens) and mixed schedules from the same manufacturer.
Journal: Expert review of vaccines
Published: June 20, 2018
Showing 1-8 of 8
Last Updated: 09/26/2026